{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:38:49Z","timestamp":1780569529939,"version":"3.54.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Discovery Today: Technologies"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.ddtec.2012.11.002","type":"journal-article","created":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T21:40:48Z","timestamp":1354398048000},"page":"e277-e284","source":"Crossref","is-referenced-by-count":33,"title":["Allosteric modulators of the extracellular calcium receptor"],"prefix":"10.1016","volume":"10","author":[{"given":"E.F.","family":"Nemeth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ddtec.2012.11.002_bib0005","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1152\/physrev.2001.81.1.239","article-title":"Extracellular calcium sensing and extracellular calcium signaling","volume":"81","author":"Brown","year":"2001","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ddtec.2012.11.002_bib0010","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1196\/annals.1346.044","article-title":"Misconceptions about calcimimetics","volume":"1068","author":"Nemeth","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ddtec.2012.11.002_bib0015","series-title":"Principles of Bone Biology","first-page":"1019","article-title":"Calcium receptors as novel drug targets","author":"Nemeth","year":"1996"},{"key":"10.1016\/j.ddtec.2012.11.002_bib0020","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/0003-9861(88)90378-5","article-title":"Regulation of hormone secretion and cytosolic Ca2+ by extracellular Ca2+ in parathyroid cells and C-cells: role of voltage-sensitive Ca2+ channels","volume":"265","author":"Muff","year":"1988","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ddtec.2012.11.002_bib0025","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1021\/jm900364m","article-title":"Antagonists of the calcium receptor. I. Amino alcohol-based parathyroid hormone secretagogues","volume":"52","author":"Marquis","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ddtec.2012.11.002_bib0030","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1073\/pnas.95.7.4040","article-title":"Calcimimetics with potent and selective activity on the parathyroid calcium receptor","volume":"95","author":"Nemeth","year":"1998","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ddtec.2012.11.002_bib0035","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0022-3565(24)29333-2","article-title":"Calcilytic compounds: potent and selective Ca2+ receptor antagonists that simulate secretion of parathyroid hormone","volume":"299","author":"Nemeth","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ddtec.2012.11.002_bib0040","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.bmcl.2005.03.054","article-title":"Design, new synthesis, and calcilytic activity of substituted 3H-pyrimidin-4-ones","volume":"15","author":"Shcherbakova","year":"2005","journal-title":"Bioorgan. Med. Chem. Lett."},{"key":"10.1016\/j.ddtec.2012.11.002_bib0045","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1021\/jm051233+","article-title":"N1-Benzoyl-N2-[1-(1-naphthyl)ethyl]-trans-1,2-diaminocyclohexanes: Development of 4-chlorophenylcarboxamide (Calhex 231) as a new calcium sensing receptor ligand demonstrating potent calcilytic activity","volume":"49","author":"Kessler","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ddtec.2012.11.002_bib0050","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1016\/j.bmcl.2010.04.035","article-title":"New aminopropandiol derivatives as orally available and short-acting calcium-sensing receptor antagonists","volume":"20","author":"Shinagawa","year":"2010","journal-title":"Bioorgan. Med. Chem. Lett."},{"key":"10.1016\/j.ddtec.2012.11.002_bib0055","doi-asserted-by":"crossref","first-page":"8501","DOI":"10.1016\/j.bmc.2010.10.035","article-title":"Synthesis and structure-activity relationship of tetrahydropyrazolopyrimidine derivatives \u2013 a novel structural class of potent calcium-sensing receptor antagonists","volume":"18","author":"Yoshida","year":"2010","journal-title":"Bioorgan. Med. Chem. Lett."},{"key":"10.1016\/j.ddtec.2012.11.002_bib0060","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1124\/jpet.110.178194","article-title":"Characterization of highly efficacious allosteric agonists of the human calcium-sensing receptor","volume":"337","author":"Ma","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ddtec.2012.11.002_bib0065","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1517\/13543776.2011.568479","article-title":"Novel calcium sensing receptor ligands: a patent survey","volume":"21","author":"Kiefer","year":"2011","journal-title":"Expert Opin. Ther. Patents"},{"key":"10.1016\/j.ddtec.2012.11.002_bib0070","first-page":"1083","article-title":"Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent","volume":"83","author":"Collins","year":"1998","journal-title":"Endocrinology"},{"key":"10.1016\/j.ddtec.2012.11.002_bib0075","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199711203372104","article-title":"Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism","volume":"337","author":"Silverberg","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ddtec.2012.11.002_bib0080","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1046\/j.1523-1755.1998.00735.x","article-title":"A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure","volume":"53","author":"Antonsen","year":"1998","journal-title":"Kidney Int."},{"key":"10.1016\/j.ddtec.2012.11.002_bib0085","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ddtec.2012.11.002_bib0090","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1210\/jc.2007-0585","article-title":"Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma","volume":"92","author":"Silverberg","year":"2007","journal-title":"J. Clin. Endocr. Metab."},{"key":"10.1016\/j.ddtec.2012.11.002_bib0095","doi-asserted-by":"crossref","first-page":"8786","DOI":"10.1074\/jbc.M110.149724","article-title":"Allosteric modulation of the calcium-sensing receptor by \u03b3-glutamyl peptides. Inhibition of PTH secretion, suppression of intracellular cAMP levels, and a common mechanism of action with l-amino acids","volume":"286","author":"Broadhead","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ddtec.2012.11.002_bib0100","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.97.9.4814","article-title":"l-Amino acid sensing by the extracellular Ca2+-sensing receptor","volume":"97","author":"Conigrave","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ddtec.2012.11.002_bib0105","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1172\/JCI9038","article-title":"Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats","volume":"105","author":"Gowen","year":"2000","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ddtec.2012.11.002_bib0110","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1210\/en.2004-1318","article-title":"A novel calcium-sensing receptor antagonist transiently stimulates parathyroid hormone secretion in vivo","volume":"146","author":"Arey","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.ddtec.2012.11.002_bib0115","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/jbmr.554","article-title":"Ronacaleret, a calcium-sensing receptor antagonist, increases trabecular but not cortical bone in postmenopausal women","volume":"27","author":"Fitzpatrick","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.ddtec.2012.11.002_bib0120","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.bone.2011.03.091","article-title":"Randomized, double-blinded placebo-controlled study of a calcilytic compound, JTT-305, in patients with postmenopausal osteoporosis","volume":"48","author":"Fukumoto","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.ddtec.2012.11.002_bib0125","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.bone.2011.04.007","article-title":"ATP936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans","volume":"49","author":"John","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.ddtec.2012.11.002_bib0130","doi-asserted-by":"crossref","first-page":"8864","DOI":"10.1074\/jbc.M512865200","article-title":"Activation of family C G protein-coupled receptors by the tripeptide glutathione","volume":"281","author":"Wang","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ddtec.2012.11.002_bib0135","first-page":"G753","article-title":"Taste receptors in the gastrointestinal tract. II. l-amino acid sensing by calcium-sensing receptors: implications for GI physiology","volume":"291","author":"Conigrave","year":"2006","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.ddtec.2012.11.002_bib0140","first-page":"S158","article-title":"NPS R-467 activation of chimeric calcium-metabotropic glutamate receptors and a calcium reception deletion mutant indicates a site of action within the transmembrane domain of the calcium receptor","volume":"11","author":"Hammerland","year":"1996","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.ddtec.2012.11.002_bib0145","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0026-895X(24)23025-X","article-title":"Domains determining ligand specificity for Ca2+ receptors","volume":"55","author":"Hammerland","year":"1999","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ddtec.2012.11.002_bib0150","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1210\/en.141.11.4156","article-title":"Effects of a calcimimetic compound and naturally activating mutations on the human Ca2+ receptor and on Ca2+ receptor\/metabotropic glutamate chimeric receptors","volume":"141","author":"Hauache","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.ddtec.2012.11.002_bib0155","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/j.1582-4934.2007.00096.x","article-title":"Structure and function of the human calcium-sensing receptor: insights from natural and engineered mutations and allosteric modulators","volume":"11","author":"Hu","year":"2007","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.ddtec.2012.11.002_bib0160","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/j.1476-5381.2009.00603.x","article-title":"Mechanisms of multimodal sensing by extracellular Ca2+-sensing receptors: a domain-based survey of requirements for binding and signaling","volume":"159","author":"Khan","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ddtec.2012.11.002_bib0165","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1124\/jpet.103.057273","article-title":"Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl","volume":"308","author":"Nemeth","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ddtec.2012.11.002_bib0170","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1365-2125.2004.02088.x","article-title":"The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis","volume":"57","author":"Ohashi","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ddtec.2012.11.002_bib0175","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1124\/jpet.110.178681","article-title":"Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion","volume":"337","author":"Henley","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ddtec.2012.11.002_bib0180","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1111\/j.1476-5381.2011.01749.x","article-title":"Biased signalling and allosteric machines: new vistas and challenges for drug discovery","volume":"165","author":"Kenakin","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ddtec.2012.11.002_bib0185","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1210\/en.2011-1426","article-title":"Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor","volume":"153","author":"Davey","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.ddtec.2012.11.002_bib0190","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ceca.2011.11.009","article-title":"Biased agonism of the calcium-sensing receptor","volume":"51","author":"Thomsen","year":"2012","journal-title":"Cell Calcium"},{"key":"10.1016\/j.ddtec.2012.11.002_bib0195","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1530\/eje.1.02007","article-title":"Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism","volume":"153","author":"Kawata","year":"2005","journal-title":"Eur. J. Endocr."},{"key":"10.1016\/j.ddtec.2012.11.002_bib0200","series-title":"The Spectrum of Mineral and Bone Disorders in Chronic Kidney Disease","first-page":"443","article-title":"Calcimimetics and calcilytics in the treatment of chronic kidney disease-mineral bone disorder","author":"Nemeth","year":"2010"},{"key":"10.1016\/j.ddtec.2012.11.002_bib0205","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/ng1295-389","article-title":"A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism","volume":"11","author":"Ho","year":"1995","journal-title":"Nat. Gen."},{"key":"10.1016\/j.ddtec.2012.11.002_bib0210","doi-asserted-by":"crossref","first-page":"13566","DOI":"10.1073\/pnas.0405516101","article-title":"Activating calcium-sensing receptor mutation in the mouse is associated with cataracts and ectopic calcification","volume":"101","author":"Hough","year":"2004","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ddtec.2012.11.002_bib0215","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1124\/jpet.109.159228","article-title":"Effect of the calcimimetic R-NPS R-568 [3-(2-chlorophenyl)-N-((1R)-1-(3-methoxyphenyl)ethyl)-1-propanamine] on correcting inactivating mutations in the human calcium-sensing receptor","volume":"331","author":"Lu","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ddtec.2012.11.002_bib0220","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1210\/jc.2008-1076","article-title":"Novel inactivating mutations of the calcium-sensing receptor: the calcimimetic NPS R-568 improves signal transduction of mutant receptors","volume":"93","author":"Rus","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ddtec.2012.11.002_bib0225","doi-asserted-by":"crossref","first-page":"E229","DOI":"10.1210\/jc.2010-0651","article-title":"Novel activating mutations of the calcium-sensing receptor: the calcilytic NPS 2143 mitigates excessive signal transduction of mutant receptors","volume":"95","author":"Letz","year":"2010","journal-title":"J. Clin. Endocr. Metab."},{"key":"10.1016\/j.ddtec.2012.11.002_bib0230","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1517\/17425255.2011.562196","article-title":"Clinical utilization of cinacalcet in hypercalcemic conditions","volume":"7","author":"Messa","year":"2011","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ddtec.2012.11.002_bib0235","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1138\/20080318","article-title":"Anabolic therapy for osteoporosis: calcilytics","volume":"5","author":"Nemeth","year":"2008","journal-title":"IBMS BoneKEy"}],"container-title":["Drug Discovery Today: Technologies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1740674912000935?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1740674912000935?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T01:25:08Z","timestamp":1745371508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1740674912000935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S1740674912000935"],"URL":"https:\/\/doi.org\/10.1016\/j.ddtec.2012.11.002","relation":{},"ISSN":["1740-6749"],"issn-type":[{"value":"1740-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}